Healthcare Industry News:  osteoporosis 

Biopharmaceuticals Oncology

 News Release - April 19, 2006

Breast Cancer Risk Dramatically Reduced With Osteoporosis Drug

Study of Tamoxifen and Raloxifene Shows High Risk Women Have Another Option for Breast Cancer Prevention

EPHRATA, Pa., April 19 (HSMN NewsFeed) -- The Pennsylvania Breast Cancer Coalition (PBCC) salutes the National Surgical Adjuvant Breast and Bowel Project (NSABP) for their breakthrough discovery in the Study of Tamoxifen and Raloxifene (STAR) clinical trial, which demonstrates the success of raloxifene (EvistaŽ) in reducing breast cancer risk for postmenopausal women at increased risk of the disease with fewer side effects than tamoxifen. Raloxifene (EvistaŽ) is currently prescribed for osteoporosis.

"These results indicate an important and significant breakthrough in our ongoing battle with breast cancer, and serve as an example of the value of clinical trials in breast cancer research and treatment," said Pat Halpin- Murphy, president and founder of the PBCC and board member of the NSABP. "Women and their oncologists will soon have the power to make a decision that could add another option in preventing invasive breast cancer with fewer side effects because of the efforts of the many women who volunteered to participate in this prevention study."

Nearly 20,000 women participated in the STAR clinical trial, making it one of the largest breast cancer prevention clinical trials ever conducted. Women who participated in the study were postmenopausal, at least 35 years old, and at an increased risk for breast cancer as determined by their age, family history, personal medical history, age at first menstrual period, and age at first childbirth.

The PBCC urges women who want to know more about the results of the STAR clinical trial and raloxifene (EvistaŽ) to contact the NSABP, the National Cancer Institute (NCI), or visit the PBCC website at http://www.pabreastcancer.org. To determine whether raloxifene may work for you, consult with your oncologist and physician.

Visit http://www.breastcancerprevention.org to calculate your breast cancer risk. A listing of Pennsylvania hospitals participating in the STAR trial can be found at http://www.pabreastcancer.org, or by calling the NCI at 1-800-4-CANCER.

The Pennsylvania Breast Cancer Coalition, founded in 1993, is a non-profit organization and the only statewide grassroots organization that speaks to and for breast cancer survivors. This year, more than 12,000 Pennsylvania women will be diagnosed with breast cancer. More than 2,300 will lose their lives to the disease. The PBCC's mission is to help find a cure for breast cancer and to improve the quality of breast cancer education, research and outreach in the state.



Source: Pennsylvania Breast Cancer Coalition

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.